Gut instinct: molecular link between COVID-19 and serotonin cells in the gut
New research may provide further evidence of the gut’s role in SARS-CoV-2 infection and disease severity with a molecular link between serotonin-producing cells in the gut and COVID-19 disease severity.
Researchers at Flinders University, Adelaide, Australia, have demonstrated a potential molecular link between COVID-19 and serotonin cells in the gut, suggesting that gut health may have a role to play in driving COVID-19 infection.
The collaborative study investigated gene expression amongst various different cell types lining the gut wall, sequencing and analysing whole genomes from thousands of individuals cells within the intestine. Specialised cells in the gut that synthesised and released serotonin were also discovered to possess a highly enriched expression of a specific SARS-CoV-2 receptor, and were the only type of cells to express all genes associated with COVID-19.
The research may provide further insight into what drives COVID-19 infection and disease severity, potentially supporting previous evidence suggesting antidepressants known as selective serotonin reuptake inhibitors could reduce the severity of COVID-19 symptoms after infection.
Damien Keating, professor and Deputy Director of the Flinders Health and Medical Research Institute and Head of the Gut Sensory Systems research group, commented: “Our study endeavoured to understand whether the gut could be a site of disease transmission and what genes might be associated with the virus entering the cells lining the gut wall.” As the exact site of infection and primary drivers of COVID-19 severity are yet to be fully understood, the researchers behind this study hope to provide important information on the gut’s role in the virus. “Our study adds further evidence that COVID-19 is far more likely to infect cells in the gut and increase serotonin levels through direct effects on the specific gut cells, potentially worsening disease outcomes,” added Keating. “As COVID-19 continues to circulate, further research will be required to advance our understanding of the gut’s role in the virus and continue to find treatment options to work alongside vaccinations.”
The study was published in leading gastrointestinal research journal Gut.
Want to know more about the gut and how it affects overall health? Read our Consumer health trends webinar roundup on the gut microbiome, or watch the webinar itself on-demand.
Source: How the gut may help to drive COVID-19 – News (flinders.edu.au)
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...